Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 1 2000
Play
Audio Below:
There
is no question that if we are giving tamoxifen to a high-risk woman
who has no concern – and here is a woman that has, let’s
say, T1 ER-positive tumor – there is no question that you have
two potential benefits. One is that whatever the small risk is there,
that will be reduced by half, and the risk of contralateral or ipsilateral
new primary will be also reduced by 50%. So, I sit down and discuss
these options very carefully with the woman who has relatively small
primary – which few years ago we would not consider anything
because the risk benefit ratio looked close to one. But now with
this major decrease in the second primary, I think then the risk
benefit ratio is more in the favor of the patient.
